Roberta Frapolli
Overview
Explore the profile of Roberta Frapolli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1861
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amodeo R, Morosi L, Meroni M, Bello E, Timo S, Frapolli R, et al.
Am J Cancer Res
. 2025 Feb;
15(1):271-285.
PMID: 39949944
Tumor Treating Fields (TTFields) applied with standard chemotherapy have been approved for the first-line treatment of unresectable pleural mesothelioma (PM), an aggressive malignancy with limited effective therapy options. In this...
2.
Craparotta I, Mannarino L, Zadro R, Ballabio S, Marchini S, Pavesi G, et al.
J Exp Clin Cancer Res
. 2024 Nov;
43(1):309.
PMID: 39587691
Background: The marine drug trabectedin has shown unusual effectiveness in the treatment of myxoid liposarcoma (MLPS), a liposarcoma characterized by the expression of the FUS-DDIT3 chimera. Trabectedin elicits a significant...
3.
Sancho-Albero M, Fenaroli A, Scaccaglia M, Matteo C, Grasselli C, Zucchetti M, et al.
ACS Omega
. 2024 Oct;
9(40):41225-41235.
PMID: 39398182
The combination of chemo- and immunotherapy was recently demonstrated to improve a patient's response to therapy, giving rise to an emerging cancer treatment known as chemoimmunotherapy (CIT). Despite the promising...
4.
Moregola A, Bonacina F, Vingiani G, Frapolli R, Turrini R, Norata G
Pharmacol Res
. 2024 Oct;
209:107442.
PMID: 39374887
Ofatumumab (OFA) and ocrelizumab (OCRE) are two anti-CD20 monoclonal antibodies approved for the treatment of relapsing forms of multiple sclerosis due to their ability to deplete B lymphocytes. The aim...
5.
Matteo C, Orienti I, Eramo A, Zeuner A, Ferrari M, Passoni A, et al.
Pharmaceutics
. 2024 Mar;
16(3).
PMID: 38543281
We describe the development and validation of a HPLC-MS/MS method to assess the pharmacokinetics and tumor distribution of fenretinide, a synthetic retinoid chemically related to all-trans-retinoic acid, after administration of...
6.
Ceruti T, Frapolli R, Ghilardi C, Decio A, Dellavedova G, Tommasi S, et al.
Molecules
. 2023 Dec;
28(24).
PMID: 38138547
We describe the development and validation of an HPLC-MS/MS method to assess the pharmacokinetics and tumour distribution of ZST316, an arginine analogue with inhibitory activity towards dimethylarginine dimethylaminohydrolase 1 (DDAH1)...
7.
Russo M, Panini N, Fabbrizio P, Formenti L, Becchetti R, Matteo C, et al.
Oncoimmunology
. 2023 Aug;
12(1):2239035.
PMID: 37538353
Chemotherapy is the standard of care for most malignancies. Its tumor debulking effect in adjuvant or neoadjuvant settings is unquestionable, although secondary effects have been reported that paradoxically promote metastasis....
8.
Sancho-Albero M, Facchetti G, Panini N, Meroni M, Bello E, Rimoldi I, et al.
Adv Healthc Mater
. 2023 Mar;
12(17):e2202932.
PMID: 36908188
Platinum-based chemotherapy is the first-line treatment for different cancer types, and in particular, for malignant pleural mesothelioma patients (a tumor histotype with urgent medical needs). Herein, a strategy is presented...
9.
Davoli E, Zucchetti M, Giavazzi R, Garattini S, Frapolli R
Ther Adv Med Oncol
. 2022 Nov;
14:17588359221136776.
PMID: 36407785
No abstract available.
10.
Ceruti T, DAlessandris Q, Frapolli R, Gopalakrishnan J, Buccarelli M, Meroni M, et al.
Pharmaceutics
. 2022 Oct;
14(10).
PMID: 36297506
Nifuroxazide (NAZ), a nitrofuran derivative used to treat diarrhea, has been recently shown to possess anticancer activity. However, its pharmacokinetic profile is poorly known. The pharmacokinetic profile of NAZ was...